Table 2 PD-L1 as a potential efficacy biomarker: response according to PD-L1 expression in NSCLC and melanoma
Tumor | PDL-1 + ve | PDL-1-ve | |
|---|---|---|---|
ORR n/N (%) | ORR n/N (%) | ||
MPDL3280A Hamid et al. ASCO #9010 | Melanoma | 4/15 (27%) | 3/15 (20%) |
Nivolumab Weber et al. ASCO #9011 | Melanoma | 8/12 (67%) | 6/32 (19%) |
Nivolumab Grosso et al. ASCO #3016 | Melanoma | 7/16 (44%) | 3/18 (17%) |
Nivolumab Topalian et al. NEJM 2012 | Melanoma | 9/25 (36%) | 0/17 (0%) |
Nivolumab Antonia et al. WCLC 2013 | NSCLC | 5/31 (16%) | 4/32 (13%) |
Pembrolizumab Garon et al. WCLC 2013 | NSCLC | 4/7 (57%) | 2/22 (9%) |
MPDL3280A Horn et al. WCLC2013 | NSCLC | 8/26 (31%) | 4/20 (20%) |
Nivolumab/ipilimumab Callahan et al. ASCO#3003 | Melanoma | 4/10 (40%) | 8/17 (47%) |